One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s own blood is modified at the bedside, or allogeneic therapies, created with ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Manually producing the TLF involves an interplay of biostatisticians, terminology coders, statistical programmers, and ...

Backed by funding from the Gates Foundation, software company Psyon is running a pilot study of a game that aims to raise ...

The European Commission has proposed new legislation to safeguard the supply of critical medicines in the EU by boosting manufacturing within the bloc and reducing dependency on suppliers from other ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although Merck is providing it to the NHS in England at a confidential discount. The new guidance is due to be finalised in April, with ...

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

The latest biotech to emerge from the Flagship Pioneering incubator – Lila Sciences – has emerged with $200 million in seed ...